Robert Rifkin, MD, Rocky Mountain Cancer Center, Denver, Colorado, discusses the ongoing, phase 3 DREAMM-7 study exploring belatanmab mafodotin in combination with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma (MM).
This study was presented at the virtual 62nd ASH Annual Meeting and Exposition.